These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2920240)

  • 1. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD.
    Valkema R; Vismans FJ; Papapoulos SE; Pauwels EK; Bijvoet OL
    Bone Miner; 1989 Jan; 5(2):183-92. PubMed ID: 2920240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
    Reid IR; King AR; Alexander CJ; Ibbertson HK
    Lancet; 1988 Jan; 1(8578):143-6. PubMed ID: 2892989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Site-dependent bone mineral density response to oral pamidronate and calcium in postmenopausal osteoporosis: a preliminary report.
    Barreira JC; Messina OD; Maldonado-Cocco JA; Roldan EJ
    Clin Rheumatol; 1997 Jun; 16(4):346-52. PubMed ID: 9259247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of intravenous pamidronate on renal function, bone mineral metabolism and bone mass in patients with severe osteoporosis.
    Hernández MV; Peris P; Monegal A; Reyes R; Muxi A; Gifre L; Guañabens N
    Am J Med Sci; 2010 Mar; 339(3):225-9. PubMed ID: 20220332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous pamidronate in the treatment and prevention of osteoporosis.
    Chan SS; Nery LM; McElduff A; Wilmshurst EG; Fulcher GR; Robinson BG; Stiel JN; Gunton JE; Clifton-Bligh PB
    Intern Med J; 2004 Apr; 34(4):162-6. PubMed ID: 15086695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats.
    Reitsma PH; Bijvoet OL; Verlinden-Ooms H; van der Wee-Pals LJ
    Calcif Tissue Int; 1980; 32(2):145-57. PubMed ID: 6773632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment of growth hormone and the bisphosphonate pamidronate, versus treatment with GH alone, in GH-deficient adults: the effects on renal phosphate handling, bone turnover and bone mineral mass.
    Valk NK; Erdtsieck RJ; Algra D; Lamberts SW; Pols HA
    Clin Endocrinol (Oxf); 1995 Sep; 43(3):317-24. PubMed ID: 7586601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study.
    Pacifici R; McMurtry C; Vered I; Rupich R; Avioli LV
    J Clin Endocrinol Metab; 1988 Apr; 66(4):747-53. PubMed ID: 3126214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclical pamidronate infusions in postmenopausal osteoporosis.
    Peretz A; Body JJ; Dumon JC; Rozenberg S; Hotimski A; Praet JP; Moris M; Ham H; Bergmann P
    Maturitas; 1996 Aug; 25(1):69-75. PubMed ID: 8887311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
    van Breukelen FJ; Bijvoet OL; Frijlink WB; Sleeboom HP; Mulder H; van Oosterom AT
    Calcif Tissue Int; 1982 Jul; 34(4):321-7. PubMed ID: 6814719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No effect of APD (amino hydroxypropylidene bisphosphonate) on hypercalcemia in patients with renal osteodystrophy.
    Hené RJ; Visser WJ; Duursma SA; Raymakers JA; de bos Kuil RJ; Dorhout Mees EJ
    Bone; 1990; 11(1):15-20. PubMed ID: 2331426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.
    Thiébaud D; Jacquet AF; Burckhardt P
    Arch Intern Med; 1990 Oct; 150(10):2125-8. PubMed ID: 2222097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate.
    Bianda T; Linka A; Junga G; Brunner H; Steinert H; Kiowski W; Schmid C
    Calcif Tissue Int; 2000 Aug; 67(2):116-21. PubMed ID: 10920215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.
    Reitsma PH; Teitelbaum SL; Bijvoet OL; Kahn AJ
    J Clin Invest; 1982 Nov; 70(5):927-33. PubMed ID: 7130396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis.
    Fromm GA; Vega E; Plantalech L; Galich AM; Mautalen CA
    Osteoporos Int; 1991 Jun; 1(3):129-33. PubMed ID: 1790400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of calcium absorption by 1,25,dihydroxy-vitamin D--studies of the effects of a bisphosphonate treatment.
    Adami S; Frijlink WB; Bijvoet OL; O'Riordan JL; Clemens TL; Papapoulos SE
    Calcif Tissue Int; 1982 Jul; 34(4):317-20. PubMed ID: 6814718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effects of pamidronate on biochemical markers of bone metabolism in osteoporosis--a placebo-controlled dose-finding study.
    Mallmin H; Ljunghall S; Larsson K; Lindh E
    Ups J Med Sci; 1991; 96(3):205-12. PubMed ID: 1810080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
    Reitsma PH; Bijvoet OL; Potokar M; van der Wee-Pals LJ; van Wijk-van Lennep MM
    Calcif Tissue Int; 1983 May; 35(3):357-61. PubMed ID: 6871766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.